With this knowledge, the authors next showed that the use of allosteric SHP2 inhibitors that prevent SHP2 from interacting with SIRPα led to synergistic responses to immunotherapy by disrupting the immunosuppressive CRC microenvironment in vivo, resulting in robust antitumor benefit as well as substantially reduced liver metastasis (17). This evidence concerns the gene SIRPA and colorectal carcinoma.